EMERSON PERIN to Prospective Studies
This is a "connection" page, showing publications EMERSON PERIN has written about Prospective Studies.
Connection Strength
0.366
-
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):169-177.
Score: 0.062
-
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J. 2014 Jul; 168(1):88-95.e2.
Score: 0.052
-
A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J. 2011 Jun; 161(6):1078-87.e3.
Score: 0.043
-
Assessing intermediate coronary lesions: angiographic prediction of lesion severity on intravascular ultrasound. J Invasive Cardiol. 2007 Oct; 19(10):412-6.
Score: 0.033
-
Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004 Sep 14; 110(11 Suppl 1):II213-8.
Score: 0.027
-
Transendocardial injection of autologous mononuclear bone marrow cells in end-stage ischemic heart failure patients: one-year follow-up. Int J Cardiol. 2004 Jun; 95 Suppl 1:S45-6.
Score: 0.026
-
Comparison of left ventricular electromechanical mapping and left ventricular angiography: defining practical standards for analysis of NOGA maps. Tex Heart Inst J. 2003; 30(1):19-26.
Score: 0.024
-
"Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017 Dec; 194:83-91.
Score: 0.017
-
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Am Heart J. 2016 09; 179:142-50.
Score: 0.015
-
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplant. 2016; 25(9):1675-1687.
Score: 0.015
-
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res. 2015 Jan 02; 116(1):99-107.
Score: 0.014
-
[Diabetic and nondiabetic patients respond differently to transendocardial injection of bone marrow mononuclear cells: findings from prospective clinical trials in "no-option" patients]. Rev Esp Cardiol. 2008 Jun; 61(6):635-9.
Score: 0.009
-
Hyperexpansion of coronary stents and clinical outcomes. Tex Heart Inst J. 2006; 33(4):437-44.
Score: 0.007
-
Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation. Tex Heart Inst J. 2004; 31(3):214-9.
Score: 0.006
-
One-year results of percutaneous myocardial revascularization for refractory angina pectoris. Am J Cardiol. 2003 Jun 01; 91(11):1342-6.
Score: 0.006
-
Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? Tex Heart Inst J. 2003; 30(3):176-9.
Score: 0.006
-
[Evaluation of post-intracoronary stent implant. Intravascular ultrasound versus quantitative angiography]. Arq Bras Cardiol. 1995 May; 64(5):439-46.
Score: 0.004